Results from phase 3 YOSEMITE and RHINE trials on faricimab in DMO

Video
Conference|ASRS

Dr Caroline Baumal provides an overview of the efficacy, safety and durability of faricimab in diabetic macular oedema (DMO) at ASRS 2021.

Dr Caroline Baumal provides an overview of the efficacy, safety and durability of faricimab in diabetic macular oedema (DMO) at ASRS 2021. In her presentation, Dr Baumal highlights results from the Phase 3 YOSEMITE and RHINE trials.

The American Society of Retina Specialists (ASRS) is hosting its 39th Annual Scientific Meeting from 8-12 October 2021, at the JW Marriott San Antonio Hill Country Resort and Spa in San Antonio, Texas.

Related Content: Additional ASRS content | Retina | Inflammation & Infection

Recent Videos
Quan Dong Nguyen, MD, MSc, of the Byers Eye Institute at Stanford University School of Medicine, discusses his presentation on Stargardt disease at the American Academy of Ophthalmology meeting
David Yorston, FRCS, FRCOphth, discusses his EURETINA keynote lecture
Hoda Shamsnajafabadi, MSc, PhD, presents at the 2024 EURETINA meeting
Timothy L Jackson PhD, MB ChB, FRCOphth, speaks about a combination therapy for VEGF-A/C/D inhibition with sozinibercept and ranibizumab
Carl Awh, MD, FASRS, speaks about the American Society of Retina Specialists (ASRS) at EURETINA
Stefano Mercuri, MD, first author of the winning eposter “Genotype-phenotype correlations in a cohort of genetically determined Retinitis Pigmentosa (RP) Italian patients with Rho gene mutations”
Bahram Bodaghi, MD, PHD, FEBO at the 2024 EURETINA meeting
Aleksandra Rachitskaya, MD, FASRS, speaks about the Vit-Buckle Society at the 2024 EURETINA Congress.
At EURETINA 2024, Martin S. Zinkernagel, MD, PhD, on the future of real-world AI use
Alexandra Miere, MD, PhD, Associate Professor of Ophthalmology, University Paris Est Créteil, France, speaks at EURETINA
Related Content
Ocuphire Pharma and Opus Genetics announce merger

Ocuphire Pharma and Opus Genetics announce merger

David Hutton
October 22nd 2024
Article

The company also announced it will seek a strategic partner to continue development of APX3330, an oral small-molecule inhibitor of Ref-1 for the treatment of non-proliferative diabetic retinopathy.

PHOTON Results and Their Relation to DME Patients in Your Practice

PHOTON Results and Their Relation to DME Patients in Your Practice

July 25th 2024
Podcast

John Kitchens, MD, is joined by Diana Do, MD, to discuss the PHOTON trial results and their relation to patients with diabetic macular oedema in clinical practice.

A road sign with a brain on it in front of a highway. Image credit: ©Prime Lens – stock.adobe.com

Alzheimer disease retinopathy and brain-to-eye β-amyloid transport

Lynda Charters
October 4th 2024
Article

The research findings highlighted a new therapeutic avenue in ocular and neurodegenerative disease

PULSAR Results and Their Relation to nAMD Patients in Your Practice

PULSAR Results and Their Relation to nAMD Patients in Your Practice

July 24th 2024
Podcast

John Kitchens, MD, is joined by David Brown, MD, to discuss the PULSAR study results and their relation to patients with neovascular age-related macular degeneration in clinical practice.

Image credit: ©Who is Danny – stock.adobe.com

What's missing in patient education?

Albert J. Augustin, MD
October 3rd 2024
Article

A different approach better serves patients with diabetic retinopathy

A phone and computer with the European Medicines Agency website. Image credit: ©Timon – stock.adobe.com

EU CHMP confirms negative opinion on marketing authorisation application of intravitreal pegcetacoplan from Apellis

Martin David Harp
September 25th 2024
Article

The agency confirmed its June 2024 negative opinion after Apellis requested re-examination of the EMA's initial response

© 2024 MJH Life Sciences

All rights reserved.